Trial Profile

A Phase 1 Clinical Trial of YTX-7739 in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs YTX 7739 (Primary)
Indications Parkinson's disease
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
Sponsors Yumanity Therapeutics

Most Recent Events

22 Apr 2021 According to an Yumanity Therapeutics Media release, data from this study will be presented at the upcoming R&D Day on May 17, 2021 and at a future medical conference.
22 Apr 2021 Results published in the Yumanity Therapeutics Media release.
31 Mar 2021 According to an Yumanity Therapeutics Media release, the company expect to report results from this trial in the 2Q 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com